Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Substantial reduction in losses
Demand normalisation post the second wave contributed to the steady growth
The company is eligible for 12 months exclusivity from launch
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
The aim is to create new genomics solutions that could combat cancer and advance market access
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Subscribe To Our Newsletter & Stay Updated
